1L KISQALI + ET + AI demonstrated an OS benefit in premenopausal patients from a dedicated randomised controlled trial vs ET + placebo*1

ET refers to LHRH plus either NSAI or tamoxifen.1

KISQALI is not recommended to be used in combination with tamoxifen.2

1L, first-line; CI, confidence interval; ET, endocrine therapy; HR, hazard ratio; LHRH, luteinising hormone-releasing hormone; NSAI, non-steroidal aromatase inhibitor; OS, overall survival.